BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

...normal iron transportation functions. As proof of concept for the delivery vehicle, Denali created an anti-BACE1...
...the unmodified anti-BACE1 antibody (38 nM vs.1 nM), and the engineered antibody decreased levels of BACE1’s...
...with the engineered antibody reaching CNS concentrations between 26- and 35-fold higher than the unmodified anti-BACE1...
BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

...Novartis AG (NYSE:NVS; SIX:NOVN) and Amgen Inc. (NASDAQ:AMGN) discontinued two Phase II/III trials of the BACE1...
...of cognitive function (see “Amyloid Hypothesis Takes First Hit in an Alzheimer’s Prevention Setting” ). BACE1...
...not restarted the prevention trial. Targets APOE - Apolipoprotein E APP - Amyloid precursor protein BACE1...
BioCentury | Oct 30, 2019
Company News

Amgen narrows neuro focus to inflammation

Despite early success for Amgen’s first marketed neurology product, the company will exit research and early development for neuroscience, narrowing its focus to neuroinflammation. “To compete effectively, we need to make investments in the areas...
BioCentury | Oct 1, 2019
Company News

Biogen turns to R&D vet as Ehlers exits

While Biogen head of R&D Michael Ehlers is departing the biotech to join the VC ranks amid a series of recent clinical disappointments, pipeline additions during his tenure could start to bear fruit over the...
BioCentury | Sep 14, 2019
Clinical News

One amyloid candidate left for Biogen, Eisai after axing BACE trials

...$236.63 on Friday; Eisai gained $0.36 to $51.03. Sandi Wong, Staff Writer BAN2401 elenbecestat (E2609) Biogen Inc. Eisai Co. Ltd. Beta-site APP-cleaving enzyme 1 (BACE1...
BioCentury | Jul 12, 2019
Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

...SIX:NOVN) and Amgen Inc. (NASDAQ:AMGN) discontinued the Phase II/III Generation studies 1 and 2 of BACE1...
...prevention trial (see "Baby Steps Beyond Amyloid" ). Targets: APOE - Apolipoprotein E; BACE1 - Beta-site APP-cleaving enzyme 1 Elizabeth...
...Beta-site APP-cleaving enzyme 1 Elizabeth S. Eaton, Staff Writer ACI-24 BAN2401 CNP520 elenbecestat (E2609) AC Immune S.A. Amgen Inc. Biogen Inc. Eisai Co. Ltd. Novartis AG Apolipoprotein E (APOE) Beta-site APP-cleaving enzyme 1 (BACE1) Alzheimer's...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | May 10, 2019
Financial News

New Eisai venture arm to focus on digital tech, dementia, cancer

As Eisai looks to digital technologies for dementia drug discovery, the Japanese pharma’s newly launched venture arm has made its first investment and backed Tokyo-based digital healthcare company Allm. Eisai Co. Ltd. (Tokyo:4523) said the...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

...is running two Phase II/III prevention trials in APOE4 carriers. GENERATION S1 is testing the BACE1...
...Medicine, St. Louis, Mo. Targets APOE4 - Apolipoprotein E ε4 APP - Amyloid precursor protein BACE1...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

...to treat Alzheimer’s disease. The targets include APP, the precursor from which β amyloid derives; BACE1...
...discontinued their compounds. The companies in green have active programs. APP - Amyloid precursor protein; BACE1...
Items per page:
1 - 10 of 196